New York, NY -- February 16, 2022 -- InvestorsHub NewsWire -- via Small Cap Specialists LLC -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research reports on NWBO, AVXL, AMRN and ENZC. TNS will be issuing a new under the radar blockchain technology stock report on 2-16-22 at market open.

Small cap biopharma company stocks have been hit hard as the stock market has consolidated, and here are four companies we think will be early rebounders. Northwest Biotherapeutics, Inc. (OTCQB: NWBO), developing DCVax® for solid tumor cancers, has received certification of their manufacturing facility in Sawston, UK. The Company has developed Phase 1A of the facility, enabling them to manufacture enough DCVax-L products for 45-50 patients per month. Meanwhile the Phase III trial of DCVax-L is continuing to move forward. Last week we saw a nice bounce (+14%) in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares as the company announced its fiscal Q1 results and updates. Anavex reported positive top-line results from the second randomized, placebo-controlled AVATAR Phase 3 study (ANAVEX®2-73-RS-002) for the treatment of adult patients with Rett syndrome. The company also advised that top-line results from the placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of Alzheimer’s disease is expected 2H 2022.The company reported cash and cash equivalents of $151.1 million on December 31, 2021.

A full research report on NWBO, and what other diseases AVXL is going into clinical trials for this year in our full report READ MORE
Copy and paste to browser may be required -

Though the company’s shares have fallen in step with the NASDAQ, Amarin Corporation plc (NASDAQ: AMRN), the makers of VASCEPA the first and only drug approved by the FDA for treatment of persistent cardiovascular risk after statin therapy, released their FYE 2021 outcome and their outlook for 2022 last month and it looks promising. Full-year 2021 total net revenue are estimated to be approximately $580 million, and the company ended 2021 with approximately $490 million in cash and investments, and no debt. Last month, Enzolytics Inc. (OTCPNK: ENZC) announced plans to begin the production of Enzolytics IPF Immune™, an immune modulator that benefits the immune system by fortifying it against infections. With the North American dietary supplements market estimated to grow from $50.11 Billion in 2020, to $77.1 billion in 2028 there is huge potential for their product. In 2020, immunity-boosting supplements had record sales, making up one-third of all new supplements sales. The company has engaged a national marketing and branding agency as its distributor to advance the product through multiple distribution channels throughout the U.S.

More about global expansion happening at AMRN that could double their revenues, and why you may want to take a deep look at ENZC in this full report READ MORE
Copy and paste to browser may be required –


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source

SOURCE: Small Cap Specialists LLC

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Northwest Biotherapeutics (QB) Charts.